200 related articles for article (PubMed ID: 23635436)
1. Impact of C-reactive protein on prognosis of patients with colorectal carcinoma.
Takasu C; Shimada M; Kurita N; Iwata T; Nishioka M; Morimoto S; Yoshikawa K; Miyatani T; Kashihara H; Utsunomiya T
Hepatogastroenterology; 2013 May; 60(123):507-11. PubMed ID: 23635436
[TBL] [Abstract][Full Text] [Related]
2. Inflammation-based prognostic system predicts postoperative survival of colorectal cancer patients with a normal preoperative serum level of carcinoembryonic antigen.
Ishizuka M; Nagata H; Takagi K; Iwasaki Y; Kubota K
Ann Surg Oncol; 2012 Oct; 19(11):3422-31. PubMed ID: 22576063
[TBL] [Abstract][Full Text] [Related]
3. Preoperative C-reactive protein as a prognostic and therapeutic marker for colorectal cancer.
Koike Y; Miki C; Okugawa Y; Yokoe T; Toiyama Y; Tanaka K; Inoue Y; Kusunoki M
J Surg Oncol; 2008 Dec; 98(7):540-4. PubMed ID: 18937231
[TBL] [Abstract][Full Text] [Related]
4. Preoperative serum C-reactive protein and its prognostic significance in patients with stage III-IV colorectal cancer.
Lumachi F; Basso SM; Santeufemia DA; Ermani M; Lo Re G; Chiara GB
Anticancer Res; 2014 Dec; 34(12):7263-6. PubMed ID: 25503158
[TBL] [Abstract][Full Text] [Related]
5. The impact of preoperative serum C-reactive protein on the prognosis of patients with hepatocellular carcinoma.
Hashimoto K; Ikeda Y; Korenaga D; Tanoue K; Hamatake M; Kawasaki K; Yamaoka T; Iwatani Y; Akazawa K; Takenaka K
Cancer; 2005 May; 103(9):1856-64. PubMed ID: 15779015
[TBL] [Abstract][Full Text] [Related]
6. Elevated C-reactive protein is associated with the tumor depth of invasion but not with disease recurrence in stage II and III colorectal cancer.
Fujii T; Yajima R; Tabe Y; Yamaguchi S; Tsutsumi S; Asao T; Kuwano H
Hepatogastroenterology; 2013 Sep; 60(126):1343-7. PubMed ID: 23933927
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of multiple molecular markers for patients with stage II colorectal cancer undergoing curative resection.
Uen YH; Lin SR; Wu DC; Su YC; Wu JY; Cheng TL; Chi CW; Wang JY
Ann Surg; 2007 Dec; 246(6):1040-6. PubMed ID: 18043108
[TBL] [Abstract][Full Text] [Related]
8. [Clinical significance of C-reactive protein in patients with stage I non-small cell lung cancer].
Shen L; Li ZM; Lu S
Zhonghua Zhong Liu Za Zhi; 2011 Jun; 33(6):442-6. PubMed ID: 21875485
[TBL] [Abstract][Full Text] [Related]
9. Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma.
Shimada H; Nabeya Y; Okazumi S; Matsubara H; Shiratori T; Aoki T; Sugaya M; Miyazawa Y; Hayashi H; Miyazaki S; Ochiai T
J Surg Oncol; 2003 Aug; 83(4):248-52. PubMed ID: 12884238
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer.
Takagawa R; Fujii S; Ohta M; Nagano Y; Kunisaki C; Yamagishi S; Osada S; Ichikawa Y; Shimada H
Ann Surg Oncol; 2008 Dec; 15(12):3433-9. PubMed ID: 18846401
[TBL] [Abstract][Full Text] [Related]
11. Serum C-reactive protein levels predict survival in hepatocellular carcinoma.
Nagaoka S; Yoshida T; Akiyoshi J; Akiba J; Torimura T; Adachi H; Kurogi J; Tajiri N; Inoue K; Niizeki T; Koga H; Imaizumi T; Kojiro M; Sata M
Liver Int; 2007 Oct; 27(8):1091-7. PubMed ID: 17845537
[TBL] [Abstract][Full Text] [Related]
12. Multivariate analysis of the prognostic value of CEA and CA 19-9 serum levels in colorectal cancer.
Reiter W; Stieber P; Reuter C; Nagel D; Lau-Werner U; Lamerz R
Anticancer Res; 2000; 20(6D):5195-8. PubMed ID: 11326694
[TBL] [Abstract][Full Text] [Related]
13. [Clinical value of preoperative serum VEGF, CRP and IL-6 levels in colorectal carcinoma].
Li ZP; Han JQ; Meng XW; Yang YF
Zhonghua Zhong Liu Za Zhi; 2010 Oct; 32(10):795-9. PubMed ID: 21163075
[TBL] [Abstract][Full Text] [Related]
14. Elevated preoperative serum C-reactive protein levels are associated with poor survival in patients with colorectal cancer.
Shibutani M; Maeda K; Nagahara H; Ohtani H; Sugano K; Ikeya T; Kimura K; Amano R; Kubo N; Tanaka H; Muguruma K; Ohira M; Hirakawa K
Hepatogastroenterology; 2014; 61(136):2236-40. PubMed ID: 25699359
[TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of smoking in addition to established risk factors in patients with Dukes B and C colorectal cancer: a retrospective analysis.
Diamantis N; Xynos ID; Amptulah S; Karadima M; Skopelitis H; Tsavaris N
J BUON; 2013; 18(1):105-15. PubMed ID: 23613395
[TBL] [Abstract][Full Text] [Related]
16. C-reactive protein is a negative independent factor in patients with stage IV colorectal cancer undergoing oxaliplatin-based chemotherapy.
Fukuchi M; Kuwabara K; Tsuji Y; Baba H; Ishibashi K; Chika N; Hatano S; Matsuzawa T; Kumamoto K; Kumagai Y; Mochiki E; Ishida H
Anticancer Res; 2013 Nov; 33(11):5051-5. PubMed ID: 24222149
[TBL] [Abstract][Full Text] [Related]
17. Tumor deposit is a poor prognostic indicator for patients who have stage II and III colorectal cancer with fewer than 4 lymph node metastases but not for those with 4 or more.
Nagayoshi K; Ueki T; Nishioka Y; Manabe T; Mizuuchi Y; Hirahashi M; Oda Y; Tanaka M
Dis Colon Rectum; 2014 Apr; 57(4):467-74. PubMed ID: 24608303
[TBL] [Abstract][Full Text] [Related]
18. Impact of C-reactive protein kinetics on survival of patients with metastatic renal cell carcinoma.
Saito K; Tatokoro M; Fujii Y; Iimura Y; Koga F; Kawakami S; Kihara K
Eur Urol; 2009 May; 55(5):1145-53. PubMed ID: 18930583
[TBL] [Abstract][Full Text] [Related]
19. Preoperative C-reactive protein in the serum: a prognostic biomarker for upper urinary tract urothelial carcinoma treated with radical nephroureterectomy.
Aziz A; Rink M; Gakis G; Kluth LA; Dechet C; Miller F; Otto W; Gierth M; Denzinger S; Schwentner C; Stenzl A; Fisch M; Burger M; Fritsche HM
Urol Int; 2014; 93(3):352-60. PubMed ID: 25138778
[TBL] [Abstract][Full Text] [Related]
20. Postoperative peak serum C-reactive protein predicts outcome of hepatic resection for hepatocellular carcinoma.
Shiba H; Furukawa K; Fujiwara Y; Futagawa Y; Haruki K; Wakiyama S; Ishida Y; Misawa T; Yanaga K
Anticancer Res; 2013 Feb; 33(2):705-9. PubMed ID: 23393371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
